Last reviewed · How we verify

Apnimed — Portfolio Competitive Intelligence Brief

Apnimed pipeline: 1 marketed, 0 filed, 2 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 9 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Period B Period B marketed melatonin receptor agonist MT1/MT2 melatonin receptor Sleep disorders
Aroxybutynin and Atomoxetine Aroxybutynin and Atomoxetine phase 3 Anticholinergic/Norepinephrine reuptake inhibitor combination M3 muscarinic acetylcholine receptor; norepinephrine transporter (NET) Urology/Neurology
AD109 AD109 phase 3 Adenosine A2A receptor antagonist Adenosine A2A receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Federico II University · 1 shared drug class
  2. Idorsia Pharmaceuticals Ltd. · 1 shared drug class
  3. Kyowa Kirin, Inc. · 1 shared drug class
  4. Massachusetts General Hospital · 1 shared drug class
  5. Merck Sharp & Dohme LLC · 1 shared drug class
  6. Shanghai Mental Health Center · 1 shared drug class
  7. Sosei · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Apnimed:

Cite this brief

Drug Landscape (2026). Apnimed — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apnimed. Accessed 2026-05-13.

Related